Display options
Cite
Tu L, Zhou P, Li L, et al. Evaluation of protective efficacy of three novel H3N2 canine influenza vaccines. Oncotarget. 2017;8(58):98084-98093doi: 10.18632/oncotarget.21104.
Tu, L., Zhou, P., Li, L., Li, X., Hu, R., Jia, K., Sun, L., Yuan, Z., & Li, S. (2017). Evaluation of protective efficacy of three novel H3N2 canine influenza vaccines. Oncotarget, 8(58), 98084-98093. https://doi.org/10.18632/oncotarget.21104
Tu, Liqing, et al. "Evaluation of protective efficacy of three novel H3N2 canine influenza vaccines." Oncotarget vol. 8,58 (2017): 98084-98093. doi: https://doi.org/10.18632/oncotarget.21104
Tu L, Zhou P, Li L, Li X, Hu R, Jia K, Sun L, Yuan Z, Li S. Evaluation of protective efficacy of three novel H3N2 canine influenza vaccines. Oncotarget. 2017 Sep 20;8(58):98084-98093. doi: 10.18632/oncotarget.21104. eCollection 2017 Nov 17. PMID: 29228675; PMCID: PMC5716715.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Sep 20;8(58):98084-98093. doi: 10.18632/oncotarget.21104. eCollection 2017 Nov 17.

Evaluation of protective efficacy of three novel H3N2 canine influenza vaccines.

Oncotarget

Liqing Tu, Pei Zhou, Lutao Li, Xiuzhen Li, Renjun Hu, Kun Jia, Lingshuang Sun, Ziguo Yuan, Shoujun Li

Affiliations

  1. College of Veterinary Medicine, South China Agricultural University, Guangzhou, Guangdong Province 510642, People's Republic of China.
  2. Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, Guangzhou, Guangdong Province 510642, People's Republic of China.
  3. Guangdong Provincial Pet Engineering Technology Research Center, Guangzhou, Guangdong Province 510642, People's Republic of China.

PMID: 29228675 PMCID: PMC5716715 DOI: 10.18632/oncotarget.21104

Abstract

Canine influenza virus (CIV) has the potential risk to spread in different areas and dog types. Thus, there is a growing need to develop an effective vaccine to control CIV disease. Here, we developed three vaccine candidates: 1) a recombinant pVAX1 vector expressing H3N2 CIV hemagglutinin (pVAX1-HA); 2) a live attenuated canine adenovirus type 2 expressing H3N2 CIV hemagglutinin (rCAV2-HA); and 3) an inactivated H3N2 CIV (A/canine/Guangdong/01/2006 (H3N2)). Mice received an initial intramuscular immunization that followed two booster injections at 2 and 4 weeks post-vaccination (wpv). The splenic lymphocytes were collected to assess the immune responses at 6 wpv. The protective efficacy was evaluated by challenging H3N2 CIV after vaccination (at 6 wpv). Our results demonstrated that all three vaccine candidates elicited cytokine and antibody responses in mice. The rCAV2-HA vaccine and the inactivated vaccine generated efficient protective efficacy in mice, whereas limited protection was provided by the pVAX1-HA DNA vaccine. Therefore, both the rCAV2-HA live recombinant virus and the inactivated CIV could be used as potential novel vaccines against H3N2CIV. This study provides guidance for choosing the most appropriate vaccine for the prevention and control of CIV disease.

Keywords: H3N2; canine influenza vaccine; inactivated CIV; pVAX1-HA; rCAV2-HA

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest.

References

  1. Infect Genet Evol. 2013 Mar;14:444-9 - PubMed
  2. J Virol. 2000 Sep;74(17):7787-93 - PubMed
  3. Virus Res. 2015 Jan 2;195:135-40 - PubMed
  4. Pathogens. 2014 Oct 21;3(4):845-74 - PubMed
  5. Vaccine. 2006 Feb 13;24(7):849-62 - PubMed
  6. Virol J. 2010 Jan 18;7:9 - PubMed
  7. Vet Microbiol. 2010 Jul 14;143(2-4):184-8 - PubMed
  8. PLoS One. 2016 Jul 14;11(7):e0159106 - PubMed
  9. Rev Med Virol. 1999 Oct-Dec;9(4):237-44 - PubMed
  10. Clin Vaccine Immunol. 2013 Jul;20(7):998-1007 - PubMed
  11. Am J Vet Res. 2007 Feb;68(2):208-12 - PubMed
  12. Virol J. 2013 Jul 09;10:227 - PubMed
  13. Infect Genet Evol. 2010 Dec;10(8):1286-8 - PubMed
  14. Mol Gen Mikrobiol Virusol. 2014;(2):22-8 - PubMed
  15. J Med Virol. 2004 Jan;72(1):138-42 - PubMed
  16. Jundishapur J Microbiol. 2015 Dec 13;8(12):e26035 - PubMed
  17. J Gen Virol. 2013 Feb;94(Pt 2):293-7 - PubMed
  18. Influenza Other Respir Viruses. 2009 May;3(3):107-17 - PubMed
  19. J Infect Dis. 2011 Jun 1;203(11):1697-8 - PubMed
  20. Vaccine. 2008 May 2;26(19):2335-43 - PubMed
  21. Clin Vaccine Immunol. 2014 Nov;21(11):1528-33 - PubMed
  22. Vet Clin North Am Small Anim Pract. 2010 Nov;40(6):1063-71 - PubMed
  23. BMC Infect Dis. 2015 Mar 04;15:114 - PubMed
  24. J Infect Dis. 2009 Dec 15;200(12):1874-83 - PubMed
  25. Vaccine. 2013 Sep 23;31(41):4508-15 - PubMed
  26. Vaccine. 2008 Sep 12;26 Suppl 4:D5-9 - PubMed
  27. Clin Vaccine Immunol. 2013 Apr;20(4):491-500 - PubMed
  28. Emerg Infect Dis. 2010 Apr;16(4):699-702 - PubMed
  29. Vet Microbiol. 2010 Aug 26;144(3-4):303-9 - PubMed
  30. Vet Rec. 2007 Jul 28;161(4):142-3 - PubMed
  31. Int J Environ Res Public Health. 2014 Sep 26;11(10):10036-50 - PubMed
  32. Vet Microbiol. 2009 Jun 12;137(3-4):359-62 - PubMed
  33. Emerg Infect Dis. 2008 May;14(5):741-6 - PubMed
  34. Vet Pathol. 2010 May;47(3):507-17 - PubMed
  35. Vet Microbiol. 2015 Feb 25;175(2-4):369-73 - PubMed
  36. Science. 2005 Oct 21;310(5747):482-5 - PubMed
  37. J Biol Chem. 2011 Mar 11;286(10):8414-24 - PubMed
  38. Curr Top Microbiol Immunol. 2015;386:301-21 - PubMed
  39. Arch Virol. 2016 Jul;161(7):1915-23 - PubMed
  40. Arch Virol. 1982;71(2):177-83 - PubMed
  41. Vet Pathol. 2017 May;54(3):527-530 - PubMed
  42. Vaccine. 2010 Nov 10;28(48):7690-8 - PubMed
  43. Vaccine. 1990 Feb;8(1):17-21 - PubMed
  44. Vet Microbiol. 2009 Nov 18;139(3-4):351-5 - PubMed
  45. J Virol. 2014 Sep 1;88(17):9693-703 - PubMed
  46. Clin Vaccine Immunol. 2015 Mar;22(3):327-35 - PubMed
  47. Jundishapur J Microbiol. 2015 Mar 21;8(3):e22570 - PubMed
  48. Vaccine. 2009 Sep 25;27(42):5740-7 - PubMed

Publication Types